CXCL12 and hepatocellular carcinoma: Due to the powerful protumor activities of CXCL12/CXCR4 axis, numerous studies have consistently shown that their expression is associated with poor prognosis for patients in esophageal cancer [202], acute myelogenous leukemia [203], BC [204,205], HCC [206], and NSCLC [207].